[{"address1": "350 Fifth Avenue", "address2": "72nd Floor Suite 7240", "city": "New York", "state": "NY", "zip": "10118", "country": "United States", "phone": "431 890 6360", "website": "https://www.hookipapharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.", "fullTimeEmployees": 151, "companyOfficers": [{"maxAge": 1, "name": "Dr. Malte  Peters M.D.", "age": 61, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 191427, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Theresa Coelho M.B.A.", "age": 61, "title": "Executive VP, CFO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 45000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Rolf M. Zinkernagel M.D., Ph.D.", "age": 79, "title": "Co-Founder", "yearBorn": 1944, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andreas  Bergthaler", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lukas  Flatz", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roman  Necina Ph.D.", "age": 55, "title": "Chief Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Klaus  Orlinger Ph.D.", "age": 45, "title": "Chief Scientific Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew L. S. Beck", "title": "Executive Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Szumera", "title": "Executive Director of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Winderlich Ph.D.", "age": 37, "title": "Chief Development Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.09, "open": 5.1, "dayLow": 5.01, "dayHigh": 5.13, "regularMarketPreviousClose": 5.09, "regularMarketOpen": 5.1, "regularMarketDayLow": 5.01, "regularMarketDayHigh": 5.13, "beta": 0.832, "forwardPE": -1.2195704, "volume": 9895, "regularMarketVolume": 9895, "averageVolume": 41138, "averageVolume10days": 16290, "averageDailyVolume10Day": 16290, "bid": 3.6, "ask": 6.52, "bidSize": 200, "askSize": 200, "marketCap": 51556836, "fiftyTwoWeekLow": 4.1, "fiftyTwoWeekHigh": 11.3, "priceToSalesTrailing12Months": 0.9883794, "fiftyDayAverage": 5.5704, "twoHundredDayAverage": 6.8522, "currency": "USD", "enterpriseValue": -10894396, "profitMargins": -0.93162, "floatShares": 6950527, "sharesOutstanding": 9655020, "sharesShort": 26771, "sharesShortPriorMonth": 95335, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.21435, "heldPercentInstitutions": 0.39762002, "shortRatio": 0.75, "shortPercentOfFloat": 0.0034999999, "bookValue": 7.14, "priceToBook": 0.7156863, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -48596000, "trailingEps": -4.12, "forwardEps": -4.19, "pegRatio": -0.19, "enterpriseToRevenue": -0.209, "enterpriseToEbitda": 0.228, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "HOOK", "underlyingSymbol": "HOOK", "shortName": "HOOKIPA Pharma Inc.", "longName": "HOOKIPA Pharma Inc.", "firstTradeDateEpochUtc": 1555594200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4fc7c674-d2aa-3bcd-a128-4deb756f8490", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.11, "targetHighPrice": 60.0, "targetLowPrice": 15.0, "targetMeanPrice": 39.83, "targetMedianPrice": 45.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 77150000, "totalCashPerShare": 6.4, "ebitda": -47709000, "totalDebt": 4898000, "quickRatio": 3.582, "currentRatio": 3.857, "totalRevenue": 52163000, "debtToEquity": 5.691, "revenuePerShare": 4.403, "returnOnAssets": -0.20096001, "returnOnEquity": -0.48988998, "freeCashflow": -46046000, "operatingCashflow": -73875000, "revenueGrowth": -0.518, "grossMargins": -0.62054, "ebitdaMargins": -0.91460997, "operatingMargins": -17.36744, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]